Business Wire

United First Partners Continues to Increase its Commitment to Research – Hires Another Four Analysts in London and New York

Del

United First Partners (“UFP”), a leading independent Equity Research, Advisory and Brokerage firm, providing event driven and special situations equities research and execution, adds four analysts in London and New York.

UFP has hired Bruno Burki, as a London based research salesperson. Prior to joining UFP, Bruno was head of event driven research at Square Global Markets and previously a senior Associate in the UK M&A team at Barclays in London, where he advised corporates and financial sponsors on a wide range of strategic transactions. Bruno notably advised ENOC in their acquisition of the minorities’ stake they didn't own in Dragon Oil, and International Power in their defence against GDF.

In addition, UFP hired Patryk Basiewicz (CFA) as a special situations analyst. Patryk joined UFP from Olivetree where he was a TMT Sector Strategist. At Olivetree, Patrick was responsible for formulation of investment ideas in European TMT equity space and handled fundamental aspects of Olivetree’s Event-driven product. Previous roles include buyside analyst positions as well as management consultant at McKinsey & Co.

The London unit also hired Josh Rosen as a special situations analyst. Prior to joining UFP, Josh was an Investment Banking Associate at Citigroup in London in the FIG group, where he worked on large-cap M&A deals across the banking and insurance sectors, as well as IPOs and capital markets financing. Prior to this, Josh held roles in Wealth & Investment Management at Citigroup and Barclays in London and Geneva where he advised Ultra High Net Worth clients.

In New York, UFP reinforced its research team with the hiring of Maggie Bishop. She joins UFP from Wells Fargo Securities in Houston where she was an Analyst in the Energy Investment Banking Group, involved in a wide variety of mergers and acquisitions, capital markets financings and strategic advisory assignments for clients across the upstream, midstream, and oilfield services sectors.

United First Partners CEO Stephane Mardel commented: “One of UFP group’s key strength is the delivery of unique, actionable and thorough research work across the globe. With the hiring of Bruno, Patryk, Josh and Maggie, UFP continues to offer one of the largest special situations research platform on the street, with diversified talents, covering multiple industries. These new hires help complement the skills of our existing established research teams in London and New York, demonstrating our commitment to producing top tier special situations research, and our desire to work relentlessly to maximise value for our clients.”

About UFP and Mariana UFP

United First Partners is an independent global financial services firm, with a strong reputation and leading position in the Equities and Derivatives space. UFP’s award winning research reflects UFP’s commitment to excellence in Special Situations Research, providing best in class and in-depth research coverage on companies where specific events may act as a catalyst for material price actions, using fundamental analysis and unique in-house legal resources. United First Partners and Mariana entered into a strategic alliance in May 2017 to generate synergies across the group’s complementary business lines and play an active role in the industry consolidation. Mariana UFP offers comprehensive cross-asset services in Europe & Australia (through Mariana UFP LLP, regulated by the FCA), in North America (through United First Partners LLC, SEC regulated and member of FINRA and SIPC) and in the UAE (through UFP Capital Markets (DIFC) Limited, regulated by the DFSA). The Mariana UFP group also offers structured products, advisory and asset management services.

Contact information

United First Partners
Stephane Mardel
+442030174330
stephane.mardel@utdfirst.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Lehman Brothers Treasury Announces Plans for Partial Wind-Down14.12.2018 17:41Pressemelding

Lehman Brothers Treasury Co. B.V. in liquidation (“LBT”) today, through its U.S. counsel Kramer Levin Naftalis & Frankel LLP, announced that LBT is planning a final cash distribution to its creditors. Professional holders of eligible notes will have the option to retain their investment by electing to receive substitute notes of one (or a few) series. Such election shall take place through a solicitation process. As a consequence, LBT will be able to reduce the number of series of notes outstanding from more than 3,700 to one or a few. Noteholders electing to receive substitute notes will be afforded the same economic entitlement to distributions received by LBT from Lehman Brothers Holdings Inc. (“LBHI”) through the substitute notes. The substitute notes will be denominated in U.S. dollars and future distributions will be made in U.S. dollars only. Noteholders who are not professional investors, or hold notes that are not eligible for substitution, or do not elect to receive substitut

Takeda Receives Positive CHMP Opinion for ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage IV Hodgkin Lymphoma in Combination with AVD14.12.2018 17:00Pressemelding

Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for the extension of the marketing authorization of ADCETRIS (brentuximab vedotin) and recommended its approval in combination with AVD in adult patients with previously untreated CD30+ Stage IV Hodgkin lymphoma. ADCETRIS is an antibody-drug conjugate (ADC) directed at CD30, a defining marker of Hodgkin lymphoma. ADCETRIS is currently not approved as a therapy for previously untreated Hodgkin lymphoma in Europe. “For a large number of previously untreated Hodgkin lymphoma patients diagnosed with Stage IV disease, progression will occur with current treatments, highlighting a true unmet need in this population,” said Anna Sureda, M.D., Ph.D., Head of the Hematology Department and Hematopoietic Stem Cell Transplant Programme, Institut Català d'Oncologia - Hospital Duran i Reynals. “In the ECHELON-1 cl

Diamond CBD, POTN Subsidiary, Enters the $46 Billion Coffee Market With the Release of Premium Line of CBD-Infused Coffee & Tea K-Kup Capsules14.12.2018 15:42Pressemelding

Diamond CBD Inc., wholly owned subsidiary of PotNetwork Holdings, Inc. (OTC Pink: POTN), a leader in hemp extraction and innovative CBD products for the wellness market, enters the Coffee segment, an industry expected to reach revenues of $46 Billion in 2018. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181214005308/en/ Experience a cup of Chill (Photo: Business Wire) Produced in accordance with a universal K-Cup design, these pods fit in almost all modern single cup coffee makers, making it an easily integrated enhancement to any environment, delivering 25mgs of CBD in a tasty favorite beverage at less than $5 per cup. This new line of premium Chill Coffee Capsules was recently added to the Company’s broad range of cannabinoid and natural hemp products. Each box comes with 4 individual capsules in original chill coffee, decaf chill coffee, chill black tea, and chill green tea flavors. The unit price for each box is $10.00

Henley & Partners Enlarges Executive Committee to Manage Expansion and Growth14.12.2018 14:00Pressemelding

Residence- and citizenship-by-investment programs have firmly established themselves over the past few years as the new frontier in terms of freedom, flexibility, and future-readiness, both for the countries issuing these programs and for the individual investors participating in them. The societal and economic value these programs generate is undisputed. The investment migration industry as a whole is currently grossing roughly USD 18 billion per year, with an expectation that it will hit the USD 20 billion mark very soon. Foreign direct investment (FDI) is now considered the lifeblood of economic growth for many developing and recovering smaller countries around the world. As such, the number of investment migration programs has been increasing rapidly, from just a handful of programs in the 1980s and 1990s to over 100 countries that now have investment migration provisions in their laws. There are more than 60 active programs today, with Moldova and Montenegro — both fast-growing Eu

Vargatef® plus docetaxel could be an option after failure of immunotherapy in lung cancer14.12.2018 09:07Pressemelding

Boehringer Ingelheim announced today the first interim results of VARGADO, an ongoing non-interventional study in routine clinical practice in Germany evaluating the efficacy and safety of Vargatef® (nintedanib) and docetaxel in patients with stage III/IV locally advanced or metastatic non-small cell lung cancer (NSCLC) of adenocarcinoma histology. The study consists of three cohorts, two of which allow for prior treatment with immune checkpoint inhibitors (ICIs) either in combination with chemotherapy in the first-line or as monotherapy in the second-line of treatment. The interim results from Cohort B (first-line chemotherapy, second-line immune checkpoint inhibitors, third-line Vargatef® plus docetaxel) were presented today at ESMO Immuno-Oncology Congress 2018 in Geneva.1 Despite a limited sample size, the VARGADO study adds to the body of evidence for nintedanib in lung adenocarcinoma following pre-treatment with chemotherapy and ICIs.1,3 The addition of nintedanib to docetaxel ha

Alps Electric to Exhibit at CES 2019 as Alps Alpine for the First Time14.12.2018 07:58Pressemelding

Japanese comprehensive electronic components manufacturer Alps Electric Co., Ltd. (TOKYO:6770) (Ota-ku, Tokyo; President: Toshihiro Kuriyama) will exhibit at CES 2019, to open at the Las Vegas Convention and World Trade Center in Las Vegas, Nevada, in the United States on January 8. Alps Electric will be taking part as a new company, Alps Alpine Co., Ltd., for the first time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181213006022/en/ Alps Alpine's new touch input device for automotive (Graphic: Business Wire) At CES 2019, an exposition of cutting-edge technologies brought together from around the world, Alps Electric will present a variety of technologies in response to the major trends in automotive development referred to as “CASE”—namely connected cars, autonomous driving, sharing and services, and electric vehicles. Making its first appearance at the show as a new company following its business integration with subs